Trial Profile
A Multi-center, Randomized, Double-blind, Crossover Study to Assess the Safety and Pharmacokinetics of Liquid Alpha₁-Proteinase Inhibitor (Human) Compared to Prolastin®-C in Subjects With Alpha₁-Antitrypsin Deficiency
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 19 Mar 2018
Price :
$35
*
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Pharmacokinetics
- Sponsors Grifols
- 24 May 2017 Primary endpoint of AUC(0-7 Days) based on antigenic content has been met, according to results presented at the 113th International Conference of the American Thoracic Society.
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 29 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.